Home Alzheimer’s Disease Adjuvant Pazopanib Does Not Improve Overall Survival for Patients With Locally Advanced...

Adjuvant Pazopanib Does Not Improve Overall Survival for Patients With Locally Advanced RCC

Adjuvant pazopanib (Votrient) treatment did not positively impact overall survival (OS) rates following resection in patients with locally advanced renal cell carcinoma (RCC), according to data from the phase 3 PROTECT trial (NCT01235962) published in the European Association of Urology.

More, pazopanib as adjuvant treatment did not improve disease-free survival in this group of patients, further confirming the existing literature regarding patients with localized or locally advanced RCC.

“These findings add to the primary outcomes from the PROTECT study [NCT01235962], which indicated that adjuvant pazopanib 600 mg does not prolong DFS following resection of locally advanced RCC,” wrote the investigators who were led by Robert J. Motzer, MD. “Survival analysis showed no difference in OS between the treatment arms. Pazopanib is not recommended as adjuvant therapy following…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments